期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

药源性骨质疏松 被引量：1

Drug-induced osteoporosis
下载PDF
导出
摘要 药源性骨质疏松(DIO)是因为长期应用影响骨代谢的药物,导致骨量减少、骨强度下降、骨微结构破坏、骨脆性增加且易于骨折的全身代谢性骨病。其中以糖皮质激素性骨质疏松症最为常见。此外,DIO的可能原因还包括:芳香化酶抑制剂治疗女性乳腺癌,抗雄激素疗法治疗男性前列腺癌,绝经后妇女服用高剂量的甲状腺素,噻唑烷二酮类药物治疗2型糖尿病,以及各种靶向免疫抑制剂药物的应用等。对于临床中使用上述对骨代谢有影响的药物,在治疗原发病的同时,需高度关注药物对骨健康的影响,临床医生应遵循标准的骨质疏松症诊疗的建议和指导方针,制定基于个体化的DIO治疗模式。
作者 巴建明 孙启虹
机构地区 解放军总医院内分泌科 抚顺市中医院
出处 《药品评价》 CAS 2014年第11期22-26,共5页 Drug Evaluation
关键词 药物 骨折 骨密度 骨质疏松
分类号 R580 [医药卫生—内分泌]
  • 相关文献

参考文献27

  • 1Johnell 0,Kanis JA.An estimate of the worldwide prevalence anddisability associated with osteoporotic fractures[J].Osteoporosis intemational,2006,17(12):1726-1733.
  • 2Kanis JA Johnell O.Requirements for DXA for the management of osteoporosisin Europe[J].Osteoporosis international,2005,16(3):229-238.
  • 3Reilly BM,Hart PD,Mascarell S,et al.Clinical problem-solving.A question wellput[J].N Engl J Med,2009,360(14): 1446-1451.
  • 4糖皮质激素性骨质疏松症诊疗指南(讨论稿)[J].中华全科医师杂志,2006,5(8):460-461. 被引量：27
  • 5Kanis JA,Johansson H,Oden A,et al.A meta-analysis of prior corticosteroid useand fracture risk[J]J Bone Miner Res,2004,19(6):893-899.
  • 6Henneicke H,Gasparini SJ,Brennan-Speranza TC,et al.Glucocorticoidsand bone:local effects and systemic iraplications[J] .Trends EndocrinolMetab,2014’25 ⑷:197-211.
  • 7Seibel MJ,Cooper MS,Zhou H.Glucocorticoid-inducedosteoporosis:mechanisms, management, and future perspectives[J].LancetDiabetes Endocrinol,2013,1(1):59-70.
  • 8Natsui K,Tanaka K,Suda M,et al.High-dose glucocorticoid treatment induces哪id \oss of trabecular bone mineral density and lean body mass[J]. OsteoporosInt, 2006,17(1): 105-108.
  • 9Ton FN,Gunawardene SC,Lee H,et al.Efifects of low-dose prednisone on bonemetabolism[J]. J Bone Miner Res,2005^0(3):464^470.
  • 10Lekamwasam S?Adachi JD’Agnusdei D,et al.A framework for the developmentof guidelines for the management of glucocorticoid-induced osteoporosisfJ].Osteoporosis intemational,2012,23(9):2257-2276.

共引文献26

同被引文献36

  • 1高莉囡,王海波,吴丹,淡以锐.化学发光免疫法检测甲状腺激素及抗体结果的临床意义[J].吉林医药学院学报,2013,34(1):10-12. 被引量：9
  • 2Somwaru LL,ArnoldAM,Joshi N,et aI.High frequency of andfactors associated with thyroidhormoneover- replacement andunder-replacement in men and women aged65 andover.JClin Endocrinol Metab. 2009;94(4): 1342-1345.
  • 3Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older adults nested case-control study. BMJ.2011;342: d2238.
  • 4Mazziotti G, Porcelli T, Patelli I, et al. Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone.2010;46(3): 747-751.
  • 5FlynnRW, BonellieSR,JungRT, etal.Serumthyroid-stimul ating hormone concentration and morbidity from cardiovascular disease and fractures in patierlts on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010; 95(1): 186-193.
  • 6Ko Y J, Kim JY, Lee J, et al. Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women.J Prev Med Public Health.2014;47(1): 36-46.
  • 7Wang Z,Zhang Q,Lu J,et al. Identification of outer membrane porin f protein of Yersinia enterocolitica recognized by antithyrotopin receptor antibodies in Graves ' disease and determination of its epitope using mass spectrometry and bioinformatics tools. JClin Endocrinol MeTab. 2010;95(8):4012-4020.
  • 8Hargreaves CE,Grasso M,Hampe CS,et al. Yersinia enterocolitica provides the link between thyroid-stimulating antibodies and their germline counterparts in Graves'disease. J Immunol. 2013; 190(11):5373 -5381.
  • 9Bianco AC,Mcaninch EA.The role of thyroid hormonend brown adipose tis sue in energy homoeostasis.Lancet Diabet & Endocr. 2013;1(3): 250-258.
  • 10Marwaha RK,Tandon N,Ganie MA,et al,Reference range of thyroid function (FT3,FT4and TSH)among Indian adults.Clin Bioche.2013;46(4):341-345.

引证文献1

二级引证文献4

药品评价
2014年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部